Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2024
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2024
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Use in Persistent (B. Microti) Babesiosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 27, 2024
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 17, 2024
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 17, 2023
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tafenoquine in Patients With Mild to Moderate COVID-19
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafenoquine
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Long-Term Safety Study of Tafenoquine
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 25, 2017
Lead Product(s) : Tafenoquine
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 16, 2016
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Medicines for Malaria Venture | Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2016
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Medicines for Malaria Venture | Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2016
Lead Product(s) : Tafenoquine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable